Clinical trials: Cancer, Head
Oesophageal Cancer
The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy
This study is to investigate the effects of narrowed gastric tube on postoperative nutritional status and the quality of life in esophageal cancer patients treated with Ivor-Lewis esopagectomy in a 12-month follow-up period.
- Trial name
- NCT01361750
- Testing
- gastric tube
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Peking University
Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
This phase II trial studies the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer.
- Conditions
- Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma
- Trial name
- NCT03146650
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Head and Neck Neoplasms
Stereotactic Radiotherapy for Sinonasal Malignancy
Sinonasal Tumors are a rare type of head and neck tumor, accounting for approximately 3% of head and neck cancers. Treatment primarily involves surgical intervention, with radiation therapy as an adjunct.
- Trial name
- NCT06617910
- Testing
- SBRT by Cyberknife
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- Taichung Veterans General Hospital
Advanced Solid Tumors Cancer
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when…
- Trial name
- NCT02988960
- Testing
- ABBV-927, ABBV-181
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Advanced Solid Tumours, Non-small Cell Lung Cancer
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
Eligible subjects will be allocated to one of four cohorts based on tumour type and presence of specific biomarker. Subjects will receive open-label Dacomitinib as tablets for oral administration on a continuous daily basis at a…
- Conditions
- Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04946968
- Testing
- Oral Dacomitinib
- Where
- 2 sites in Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Nasopharyngeal Carcinoma
Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
Malnutrition is very common in locally advanced nasopharyngeal carcinoma(NPC) patients undergoing current chemoradiotherapy (CRT) due to dysphagia, mucositis, nausea and other treatment-related problems.
- Trial name
- NCT02776124
- Testing
- Healing Elements,Methuselah Medical Technology
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Thyroid Nodule, Thyroid Cancer
The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer
The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is: What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)?…
- Trial name
- NCT06929650
- Testing
- Radiofrequency ablation
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Head and Neck Cancer
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002735
- Testing
- Induction chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Basal Cell Cancer, Eyelid Tumor
Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma
The goal of this clinical trial is to evaluate the safety, tolerability, and clinical outcomes of a dose-modulation strategy of Sonidegib in adult patients with locally advanced periocular basal cell carcinoma (laBCC) who are not…
- Conditions
- Basal Cell Cancer, Eyelid Tumor, Basal Cell Carcinoma (BCC), Basal Cell Carcinoma of the Head and Neck
- Trial name
- BCC-Sonidegib (NCT07068568)
- Testing
- Sonidegib
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Federico II University
Thyroid Cancer
Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)
Thyroid cancer is a universally relatively rare neoplasm, accounting for nearly 1-5% of all female cancers and less than 2% of male cancers.
- Trial name
- NCT07056218
- Testing
- neck ultrasound, thyroglobulin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Esophageal Cancer
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR.
- Trial name
- NCT07573397
- Volunteers
- 88 people
- Sponsor
- Fudan University
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
HNSCC, Head and Neck Squamous Cell Carcinoma
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06693323
- Testing
- AHCC®capsules
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Irvine
Thyroid Cancer
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
The purpose of this study is to find out if the drug AZD6244 can improve the radioactive iodine uptake by the patient's metastatic thyroid cancer.
- Trial name
- NCT00970359
- Testing
- AZD6244
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Two randomized trials of reirradiation after salvage surgery have been conducted by the GETTEC and GORTEC collaborative groups, both members of the French HN Intergroup: The first trial compared reirradiation and a "wait and see…
- Trial name
- ADJORL1 (NCT03406247)
- Testing
- Nivolumab, Ipilimumab
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.